FDA Panel Backs Denial of Pediatric Myopia Drops

An FDA advisory committee sided with the agency's own reviewers on 30 October 2026, finding that Sydnexis has not shown its investigational eye drop, SYD-101, slows the progression of myopia in children reliably enough to support approval. The meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee was unusual in its origin: Sydnexis itself asked for it, filing a formal dispute of FDA's October 2025 rejection rather than simply resubmitting data. The panel's discussion gave the agency's statistical concerns a public airing — and did not resolve them in the sponsor's favor.

A dispute hearing, not a first look

Most FDA advisory committee meetings happen before an action date, while a new drug application is still under review. This one happened after a rejection, as part of a Formal Dispute Resolution Request — a sponsor-initiated process for contesting an FDA decision through the agency's Office of Specialty Medicine rather than through the courts or a simple resubmission. FDA had told Sydnexis, after the October 2025 complete response letter, that the STAR trial's primary endpoint was technically met but that the overall case for effectiveness was weak; Sydnexis disagreed, and the dispute-resolution pathway is what put the question in front of an outside panel at all. That the agency agreed to hold a public meeting over a dispute, rather than resolve it administratively, signals FDA treated the underlying science as genuinely contestable, even if the panel ultimately did not side with the sponsor.

What the panel actually found

Over the course of the meeting, committee members worked through four specific concerns FDA had raised about the STAR trial and the literature Sydnexis submitted to support it. Members identified weaknesses in both: the trial's primary endpoint, while statistically positive, rested on a result members called borderline and fragile, compounded by a meaningful amount of missing patient data that complicates any confident read of the effect size. Acting chair Michael Repka summarized the committee's position directly — the trial was positive, but, in his words, it was not a robust outcome that would meet the standard FDA applies for approval. That framing matters for how Sydnexis proceeds: a panel finding of outright invalid data would point toward abandoning the endpoint, while a finding of a real but statistically fragile effect leaves room for a larger or better-controlled trial to settle the question.

A drug already approved elsewhere

SYD-101 is not a novel molecule seeking its first regulatory green light anywhere. Low-dose atropine formulations for slowing pediatric myopia are already approved in the EU and the UK, and clinicians in both markets have prescribing experience FDA's reviewers do not. That divergence is a recurring feature of pediatric ophthalmology, where US trial design standards and endpoint definitions have at times run stricter than those abroad, and it is the backdrop against which Sydnexis's dispute plays out: the company can point to an approved product elsewhere, while FDA's reviewers and now this panel remain focused narrowly on whether the US pivotal trial, specifically, clears the domestic evidentiary bar. Sydnexis said after the meeting that it remains confident in SYD-101's potential and looks forward to continued discussions with FDA as it works toward a path to approval, citing close to 60 written public comments submitted in the drug's support. The dispute now returns to FDA's Office of Specialty Medicine, which is not bound by the committee's discussion but will weigh it heavily in deciding whether the October 2025 rejection stands.

Frequently asked questions

What is SYD-101?

A 0.01% atropine ophthalmic solution from Sydnexis intended to slow myopia progression in children. No drug is currently FDA-approved for that indication in the US, though atropine-based products for pediatric myopia are already approved in the EU and UK.

Why did FDA convene an advisory committee on 30 October 2026?

FDA rejected Sydnexis's NDA in October 2025, finding the pivotal STAR trial met its primary endpoint but that the data did not support effectiveness. Sydnexis filed a Formal Dispute Resolution Request with FDA's Office of Specialty Medicine, and this meeting was convened as part of resolving that dispute.

What did the committee decide?

Members found weaknesses in the trial and its supporting literature, agreeing with FDA that the primary endpoint result was borderline and statistically fragile with substantial missing data. Acting chair Michael Repka said the result was positive but not robust enough to meet FDA's standard for approval.

What happens to SYD-101 now?

Sydnexis says it remains confident in the drug and looks forward to continued discussions with FDA. The dispute returns to FDA's Office of Specialty Medicine, which weighs the committee's discussion but makes the final call on whether the 2025 rejection stands.